Search

Source at https://vkm.no/ The Norwegian Food Safety Authority (NFSA) and Norwegian Environmental Authority (NEA) asked the Norwegian Scientific Committee for Food Safety (Vitenskapskomiteen for mattrygghet, VKM) for an opinion on factors associated with the introduction of Chronic Wasting Disease (CWD) to Norway. VKM appointed a working group consisting of two members of the Panel on Biological Hazards, one member of Panel on Animal Health and Welfare, and two external experts to prepare the answer to the questions. The Panel on Biological Hazards has reviewed and revised the draft prepared by the working group and approved the opinion. Mattilsynet og Miljødirektoratet har bedt Vitenskapskomitéen for mattrygghet (VKM) om å besvare spørsmål knyttet til mattrygghet og dyrehelse etter at den uhelbredelige sykdommen Chronic Wasting Disease (CWD) nylig ble påvist hos en villrein og senere hos to elger i Norge. VKM nedsatte en arbeidsgruppe bestående av to medlemmer fra Faggruppen for hygiene og smittestoffer, ett medlem fra Faggruppen for dyrehelse- og velferd samt to eksterne eksperter, for å utarbeide en vurdering knyttet til de stilte spørsmålene. Faggruppen for hygiene og smittestoffer har lest utkast til rapporten og godkjent vurderingen.

The Norwegian Food Safety Authority (NFSA) and Norwegian Environmental Authority (NEA) asked the Norwegian Scientific Committee for Food Safety (Vitenskapskomiteen for mattrygghet, VKM) for an opinion on factors associated with the introduction of Chronic Wasting Disease (CWD) to Norway. VKM appointed a working group consisting of two members of the Panel on Biological Hazards, one member of Panel on Animal Health and Welfare, and two external experts to prepare the answer to the questions. The Panel on Biological Hazards has reviewed and revised the draft prepared by the working group and approved the opinion.

Source at https://vkm.no/ The Norwegian Scientific Committee for Food Safety (VKM) has appointed an ad hoc-group of experts to answer a request from the Norwegian Food Safety Authority regarding benefit and risk assessment of Lactobacillus paracasei ssp. paracasei F19 (F19) in processed cereal-based baby foods intended for small children 1-3 years. This assessment is based on the literature provided by the notifier as well as that found by a MEDLINE search. Vitenskapskomiteen for mattrygghet (VKM) har på oppdrag fra Mattilsynet utarbeidet en nytte- og risikovurdering av Lactobacillus paracasei ssp. paracasei F19 (F19) tilsatt i barnegrøt til barn i alderen 1-3 år. For å besvare oppdraget nedsatte VKM en ad hoc-gruppe. Vurderingen er basert på gjennomgang av litteratur tilsendt fra virksomheten og MEDLINE litteratursøk.

Source at https://vkm.no/ The Norwegian Scientific Committee for Food Safety (VKM) has appointed an ad hoc-group of experts to answer a request from the Norwegian Food Safety Authority regarding benefit and risk assessment of B. lactis Bb12 in baby foods focusing on the age groups 4-6 months, 6-12 months and 1-3 years. This assessment is based on the literature provided by the notifier as well as that found by a MEDLINE search. Vitenskapskomiteen for mattrygghet (VKM) har på oppdrag fra Mattilsynet utarbeidet en nytte- og risikovurdering av B. lactis Bb12 med fokus på aldersgruppene 4-6 måneder, 6-12måneder og 1-3 år. For å besvare oppdraget nedsatte VKM en ad hoc-gruppe. Vurderingen er basert på gjennomgang av litteratur tilsendt fra søker og MEDLINE litteratursøk.

Source at https://vkm.no/ Forbruket av krydder i Norge øker og ligger per i dag på vel ½ kg per person og år (2006). Forbruket hos oss er imidlertid fortsatt langt lavere enn i enkelte andre industriland (eksempelvis USA med et forbruk på 1,6 kilo per person og år) og vil derfor sannsynligvis fortsatt øke ganske betydelig. Også antall ulike kryddertyper øker, parallelt med økende interesse for ”eksotisk” (ikke minst asiatisk) mat. Faggruppen for hygiene og smittestoffer i Vitenskapskomiteen for mattrygghet startet denne egeninitierte saken for å belyse mulig sammenheng mellom krydder som smittekilde og tarmpatogene bakterier isolert fra mennesker (f. eks Salmonella og E. coli) i Norge.

On 10. March 2006 , The Norwegian Food Safety Authority (Mattilsynet) decided that, on the basis of VKM’s previous risk assessment (2005), Nutramigen 1 with Lactobacillus rhamnosus GG (LGG) could not be marketed in Norway as medical foods for infants (0-4 months). In addition, The Norwegian Food Safety Authority (Mattilsynet) decided (08. November 2006) to withdraw permission for marketing of Nutramigen 2 with LGG, which is a milk supplement for infants aged between 4 and 6 months, with cow’s milk and soy protein allergy. On 13. December 2006, Mead Johnson Nutritionals appealed against this decision from The Norwegian Food Safety Authority (Mattilsynet). The Norwegian Food Safety Authority forwarded the appeal from the companies, asked the VKM Panel on biological hazards and the VKM Panel on nutrition, dietetic products, novel food and allergy, for a new risk assessment including the new data provided in the appeal. LGG is one of the most studied probiotic strains. Lactic acid produced by LGG in the human gut results in a decrease in faecal pH, which in turn inhibits colonisation by potentially pathogenic bacteria. Short-term beneficial effects from administration of LGG to infants and young children with infectious diarrhoea have been reported in a number of studies, but a prophylactic effect on diarrhoea has not been documented. Furthermore, whilst some studies have reported a prophylactic, or even a curative, effect of LGG on atopic eczema in young children, more recent studies do not report such effects. Some even suggest an increased incidence of allergic sensitization in children receiving LGG supplemented formula at an early age. There are no published data that demonstrate long-term clinical benefits of infant formula supplemented with LGG for children between 4 months and 3 years, although no immediate deleterious effects of LGG have been found. Possible long-term effects of LGG on intestinal colonisation, and its effects on long-term gastrointestinal and immune functions, are not known. LGG, as an ingredient in infant formula and baby foods, is intended for daily use in the target group, and not for short-term, specific treatment. Furthermore, the targeted consumer group includes children below the age of twelve months. These two aspects demand particular consideration with regard to the unknown effects of longterm treatment with large doses of live bacteria on the ecology of the microbiota of the gastrointestinal tract and on the immune system. Neither of these systems is fully matured in infants and small children, and therefore may be particularly susceptible. Norwegian Scientific Committee for Food Safety There is no documented prophylactic effect of LGG on any disease in children. The effect of treatment with LGG-supplemented formula in small children is questionable, except for a documented short-term effect on infectious diarrhoea. Panel on Biological Hazards and Panel on nutrition, dietetic products, novel food and allergy at the Norwegian Scientific Committee for Food Safety find that the data available are not sufficient to support the suggested beneficial effects, or the safety, of LGG in infant formula and baby foods for children aged between 4 months and 3 years, when the products are intended for daily use.